LPSN Archives - Page 2 of 2 - Blue Horseshoe Stocks

Blue Horseshoe Stocks: AAN, RFMD, FTNW & Extended Watchlist

Aarons, Inc. AAN – Options

One item of interest that we’ve been waiting to touch upon is AAN. We’ve watched as the stock has taken quite a beating over the past few weeks, and are presently scanning for a bottom. After losing so much ground over so short a time period, when support is found, the recovery on AAN could end up allowing for some rapid profits in the options chain.

While we need to first observe a solid base of support before setting our short-term call strategy, there are already a pair of longer-term contracts that we’re going to put on watch. The November 22nd $29 and $30 Calls (trading yesterday at 3.20 and 2.05, respectively) could see significant rises in value once a reversal occurs on the chart.

RF Micro Devices, Inc. RFMD

We brought RFMD up as a topic of discussion this past Friday, mentioning that the spike catalyzed by the release of record revenues was likely to lead to a classic ‘dip-and-rip’ scenario. That keen instinct has thus far paid off, as the stock did indeed dip to 10.74 before rebounding as high as 11.79 (+10%), achieving higher lows each day over the past four sessions.

As a result of the trend, we’re going to have our eyes on the September $12 Calls, which closed at .70 yesterday.

FTE Networks, Inc. FTNW

FTNW hit our news scanner this morning and will be a stock that we monitor as the trading session opens today. The PR alludes to some lucrative contracts, so we’ll be interested to see how it reacts to such significant press.

FTE Networks Announces $22 Million in New Contracts (Thu 8:15AM EDT)

Extended Watchlist:
LPSN, FCEL, EVRY, ROSG, USU, JRN, TSLA (Earnings report)

GERN, MACK, ADSU, ACDU & Extended Watchlist

Yesterday’s OTC Shutdown

We wanted to comment on the lack of OTC trading yesterday even though our newsletter didn’t happen to contain any OTC stocks. Due to an alleged glitch in connectivity, FINRA made the call to halt all trading on the OTC Markets. It took most of the day for a solution to be enacted, but apparently the problem was resolved, and trading will resume normally today. This wasn’t the first time this year that a US Market has been shut down for glitches in data streams, as many you of recall, NASDAQ was hit with a similar occurrence which forced a halt back in August.

Geron, Corp. GERN

We added GERN to yesterday’s extended watchlist upon witnessing pre-market trades going off in the 4.00-range. It was gapping up big-time from its previous close at 3.60, and began the day’s trading at 7.25. This was a red flag, and as is usually the case with a stock which has spiked so violently, GERN hit its top at 7.79, and began the inevitable reversal. This would have been an excellent opportunity to short the stock, and cover in the 5.00-range for a rapid profit to the tune of 40%

Merrimack Pharmaceuticals, Inc. MACK

MACK is a bottom-bounce play that we picked up on yesterday, and like it as a potential recovery play. There is a big gap on the chart between the 3.00-3.40 level, the filling of which could provide us with gains of 30% or more. We’ll have it on watch today to break that 3.00-mark.

Aden Solutions, Inc. ADSU
&
Accredited Business Consolidators Corp. ACDU

We noticed that these two plays began to breakout yesterday on abnormally high volume. We want to keep them on watch for a continuation of that momentum into today’s session.

Gainers From Yesterday’s Watchlist

Here are picks from yesterday’s extended watchlist that fared well and offered us the chance at gains:

NeuroMetrix, Inc. NURO saw a low of 2.38, and ran 20% to 2.85 roughly between the hours of 10am-1pm

LivePerson Inc. LPSN touched a low of 10.61 before hitting its daily high at 11.44, an 8% increase.

Extended Watchlist:
PPHM, GRPN, RVLT, OXBT, SUNE

OXBT, MCHX, TWTR & Extended Watchlist

Oxygen Biotherapeutics, Inc. OXBT
–
OXBT followed our expectations to the letter yesterday. We were heralding the stock for its stellar 560% gain, then mentioned that we would be “on alert for any possible pullbacks, because those will often lead to excellent bounce opportunities.” The monstrous run that had begun a few days prior found its apex, giving way to a significant consolidation. After opening at 9.73, OXBT went as high as 11.40, that’s 17% intraday, and from our original alert low of 1.46 (10/29), a tremendous 681%

Upon the anticipated pullback we saw the stock fall to 6.81, bounce, close at 7.70, and this morning pre-market trades have been going off above the 8.00-mark. Moving forward we’d like to see the stock hold support above yesterday’s low, and continue to make higher lows.

This whole thrill ride was catalyzed when OXBT’s partner Phyxius Pharma announced testing results on its heart medication, ‘Levosimendan’, which showed effectiveness in reducing mortality rates among patients undergoing surgical procedures with reduced cardiac function.Tests at the Duke School of Medicine showed it could potentially reduce unwanted outcomes from open heart surgery by as much as 50%. OXBT has a standing agreement to acquire Phyxius, and by extension, the rights to Levosimendan. This is a story we will continue to follow through to its conclusion.

Marchex, Inc. MCHX

MCHX appeared in yesterday’s extended watchlist and made a nice move, trading in a range from 8.17 to 10.00. That represents a 22% gain, and the stock did manage to close out the session maintaining much of that increase at 9.91.

The Twitter IPO – TWTR

As many of you undoubtedly know, on Wednesday, Twitter priced its shares at $26, and will begin trading on the NYSE today under the symbol TWTR. As we did with Facebook, we are using caution early on, as the conditions seem set to create a “perfect storm” of volatility out of the gate. Demand from the outset is expected to be very high, which would create buying pressure and likely cause a significant increase as the first shares begin trading hands. Some experts believe as much as a 30% initial spike could occur, which we believe would lead a sizable number of investors to take those quick profits off of the table right away. That wave of selling pressure could kick up the volatility, causing some major swings in share price.

On the other hand, if demand for the stock has been underestimated, we could be looking at a maiden run that spans multiple sessions. This is why, and the Facebook IPO certainly provided a good lesson to that effect, we are approaching TWTR with a healthy skepticism. No matter how it all plays out, it will be very interesting to watch. You can be sure we will continue to comment as the situation unfolds.

Extended Watchlist:
GSS, JCP, OXGN, LPSN, NURO, GERN, AGEN(Coming off of recent lows)